Skip to search formSkip to main contentSkip to account menu

melflufen

Known as: melphalan-flufenamide 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

MelphalanPhenylalanine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).
e20570Background: Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells… 
2019
2019
Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed…
Background: Recent advances have improved survival in multiple myeloma (MM; Kumar et al. Leukemia. 2014); however, the disease… 
2019
2019
The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on…
Background: Due to advances in therapy, outcomes have improved in multiple myeloma (MM). However, the improvement in overall… 
2019
2019
OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis
Background: AL amyloidosis is a rare life-threatening disease arising from a disorder of plasma cells resulting in excessive… 
Review
2019
Review
2019
Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1
Background: Patients with multiple myeloma (MM) who have relapsed after conventional treatment have limited therapeutic options… 
2018
2018
The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1…
Background : Recent improvements in the treatment of relapsed-refractory multiple myeloma (RRMM) have significantly increased… 
2017
2017
First Report on Overall Survival (OS) and Improved Progression Free Survival (PFS) in a Completed Phase 2a Study of Melflufen in Advanced Relapsed Refractory Multiple Myeloma (RRMM)
Background: Melflufen is a next generation alkylator, designed for efficient targeting of tumor cells with a unique mechanism of… 
2017
2017
Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide: A Report on Early Efficacy
Background: Melflufen is a next generation alkylator, designed for efficient targeting of tumor cells with a unique mechanism of… 
2015
2015
Anticancer Activity of Melflufen : Preclinical Studies of a Novel Peptidase-Potentiated Alkylator
Melflufen (melphalan flufenamide, chemical name L-melphalanyl-p-L-fluorophenylalanine ethyl ester hydrochloride, previously… 
2014
2014
Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and…
Background: Melphalan is widely used in the treatment of Multiple Myeloma (MM), both as a low dose agent in elderly patients and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)